Biotechnology
Medical
Biopharmaceutical

Regeneron

$299.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.05 (0.35%) Today
$0.00 (0.00%) As of 5:53 PM EDT after-hours

Why Robinhood?

You can buy or sell Regeneron and other stocks, options, ETFs, and crypto commission-free!

About REGN

Regeneron Pharmaceuticals, Inc. Common Stock, also called Regeneron, is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Read More It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Employees
7,400
Headquarters
Tarrytown, New York
Founded
1988
Market Cap
32.70B
Price-Earnings Ratio
14.12
Dividend Yield
0.00
Average Volume
892.03K
High Today
$303.30
Low Today
$297.08
Open Price
$297.26
Volume
646.32K
52 Week High
$442.00
52 Week Low
$287.66

Collections

Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Health
Technology

REGN News

ReutersJun 26

FDA approves expanded label for Regeneron/Sanofi's Dupixent

294
Yahoo FinanceJun 21

Regeneron And Sanofi Tried To Outperform Themselves — And Couldn't

312
Yahoo FinanceJun 21

Here's Why AnaptysBio Shares Are Sliding Today

314

REGN Earnings

$4.32
$5.16
$6.00
$6.84
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Available Aug 6, Pre-Market

Popular Stocks

More REGN News

Yahoo FinanceJun 21

Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

12
Seeking AlphaJun 21

AnaptysBio -13.8% on Regeneron data, downgrades

163
Seeking AlphaJun 21

Sanofi and Regeneron presents REGN3500 data

44
MarketWatchJun 21

Regeneron, Sanofi have positive asthma drug trial

25
Yahoo FinanceJun 20

Implied Volatility Surging for Regeneron Stock Options

16
Seeking AlphaJun 18

Regeneron loses a bull as threats to Eylea rise

145
Barron'sJun 18

Regeneron Stock Faces More Uncertainty as Rivals Gear Up, Analyst Says

70
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.